AzTrials
AzTrials

Pulmonary HypertensionNCT01972009

Wave Intensity Analysis in the Pulmonary Artery

An observational study of Pulmonary Hypertension, run by Imperial College London at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The mechanism governing how blood flows from the heart to the lungs depends on many factors including the pumping function of the right ventricle, properties of the arteries that carry the blood from the right ventricle to the lungs (pulmonary arteries), and the lungs themselves. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Pulmonary Hypertension
What is being tested?
Cardiac catheterisation
Type of treatment
Surgery or procedure
How many people
36 participants
Where
1 siteUnited Kingdom
Study dates
Oct 2013to Sep 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients with normal pulmonary pressures will be recruited from patients who are on the waiting list awaiting routine cardiac catheterisation at Hammersmith Hospital for the investigation of shortness of breath and chest pain. Patients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service, Hammersmith Hospital, who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work up.

Who may be able to join

  • Adult patients undergoing right and left heart catheterisation.

Who cannot join

  • under 18 years of age
  • atrial fibrillation
  • chronic renal failure (eGFR <30)
  • unable to exercise
  • unable to consent
  • pulmonary embolism in the last 3 months

Trial locations and contacts

1 site in 1 country.

Charlotte Manisty, MRCP PHD contact

+44 (0)2075841264

cmanisty@ic.ac.uk

United Kingdom1 site
  • National Heart and Lung Institute, Imperial College London

    London, London, W2 1LA

    Charlotte Manisty, MRCP PHD, +44 (0) 2075841264, cmanisty@ic.ac.uk

    Junjing Su, MD, +44 (0) 7462855344, junjingsu@hotmail.com

Other trials in United Kingdom

About this study

Official title: Systematic Assessment of Pulmonary Artery Haemodynamics Using Wave Intensity Analysis

The mechanism governing how blood flows from the heart to the lungs depends on many factors including the pumping function of the right ventricle, properties of the arteries that carry the blood from the right ventricle to the lungs (pulmonary arteries), and the lungs themselves.

Under normal conditions the pressure in the pulmonary arteries is well controlled and significantly lower than in the systemic circulation, however there are a number of conditions that lead to abnormally high pressures and significant morbidity and mortality.

Read more

However different patients respond differently to similarly elevated pressures, leading doctors to believe that there must be differences in either the right ventricles, the properties of the arteries, or the lungs themselves. It can be difficult to determine the relative contributions of each of these factors on blood flow because their effects are superimposed on each other.

One approach that has been used to look at this in other parts of the circulation (including in the systemic circulation and the coronary arteries) is to measure simultaneous pressure and flow, and apply a technique called wave intensity analysis (WIA). This technique can amongst other things, quantify the separate effects of wave reflection and the 'reservoir function' (or compliance) of the arteries, and in the systemic circulation WIA has increased the understanding of the mechanisms behind hypertension and the physiological changes of ageing. The pulmonary arteries are accepted to be very different from the systemic circulation and the mechanisms behind pulmonary hypertension are thought to be very different to those of systemic hypertension.

This protocol aims to determine the major influences on blood flow in the pulmonary arteries in health and disease, to help to understand why some patients are affected more than others by elevated pulmonary pressures.

Read the detailed description

Purpose Currently best clinical practice for the investigation of pulmonary hypertension (raised pulmonary pressures) involves patients attending the catheter laboratory and catheters being passed under fluoroscopic guidance via the femoral vein to measure right heart pressures (and generally also via the femoral artery and aorta to measure left sided pressures). Wave intensity analysis using simultaneous pressure and flow measurements gives additional information about the upstream and downstream effects on haemodynamics, and we propose will lead to a more detailed assessment of the influences both causing and exacerbating pulmonary hypertension. Until recently it has not been possible to assess these effects formally: the standard technique measures only local pressure.

Design This protocol will involve passing catheters as per usual practice into the pulmonary arteries and aorta. A Combiwire (a standard pressure and flow measurement wire which has been available commercially and used worldwide for the past 5 years for making physiological measurements in the coronary arteries) will then be advanced approximately 1cm beyond the end of the catheter. Participants will have the usual clinical protocol of left and right heart catheterisation (and coronary angiography if clinically indicated) and the simultaneous pressure and flow measurements will be made in addition. Participants will also have noninvasive imaging (echocardiography and, if clinically indicated, cardiac MRI) and serum biochemical measures, as per usual clinical practice. They will also undergo cardiopulmonary exercise testing to assess their lung and cardiac capacity.

Recruitment The investigators will recruit patients with pulmonary hypertension from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work up. Patients with normal pulmonary pressures will be recruited from patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain. Recruitment will involve a discussion with the patient and printed material that the patient can refer to. They will be fully aware of the additional measurements being made, and no therapeutic promises will be made.

Development of Research Proposal Interventional cardiologists, pulmonary hypertension specialists, clinical scientists and basic scientists have been involved with the development of this protocol. All members have been involved in critiquing the proposal. The investigators have also consulted patients who have been involved in previous research conducted during angiography regarding the number of hospital visits and additional time required during the procedure for data collection.

Consent All patients will be consented for the study by the research Fellow who will be a Cardiology SpR (MBBS, MRCP) or Pulmonary Hypertension Specialist. She will be able to assess capacity and understand the ethical principles underpinning informed consent.

Risks, burdens and benefits The risk of using pressure and flow wires: The wires will be advanced approximately 1cm outside the guide catheter that is used in routine clinical practice. In the pulmonary artery the wire will be positioned approximately 15cm more proximal than where the balloon is inflated during conventional pulmonary capillary wedge pressure measurement. In a recently published study of >7000 patients undergoing right heart catheterisation, there was only one incidence of pulmonary artery dissection. Damage to the arteries will be minimised by using an experienced interventional cardiologist to perform the procedures. The investigators have extensive knowledge in making these measurements resulting in minimal risk to the patient. To date no patient has had an adverse event secondary to the use of the pressure and flow wires in either the pulmonary arteries, aorta or coronary arteries. A pilot safety and feasibility study in 23 patients undertaken at the Royal Brompton Hospital in both normal subjects and those with pulmonary hypertension of various aetiologies showed that measurements of pressure and flow using Combiwires in the pulmonary arteries are possible in patients studied and there were no complications.

Confidentiality The Caldicott Principles for use of identifiable data will be used. In accordance with University and NHS policy, to ensure satisfactory integrity both of research data and confidential patient information, the procedural data will be stored in anonymised form on a fully archived hard disk drive, with additional backup on long term optical storage media, while patient identifiable data will be stored on computers located within the NHS facility. Linkage between them will be in the form of paper records, which will be retained within the NHS premises. If confidentiality needs to be broken we will seek advice from the local ethics committee.

Conflict of Interest We have no conflict of interest. The patients involved in this study will be informed via an information leaflet of the results and what they mean at the end of the study.

Being tested
Cardiac catheterisation
Medical subject headings
Hypertension, Pulmonary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cardiac catheterisationProcedure or surgery

    Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.

Study groups in NCT01972009
Study groupRoleWhat they receive
Subjects without pulmonary hypertensionPatients with normal pulmonary pressures will be recruited amongst patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
Receives: Procedure: Cardiac catheterisation
Subjects with pulmonary hypertensionPatients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work-up.
Receives: Procedure: Cardiac catheterisation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Wave reflection coefficient

    Measured: 6 months

Secondary outcomes (1)
  1. Reservoir function

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2013 (estimated)
  2. Study startOct 2013
  3. Primary completionSep 2015 (estimated)
  4. Study completionSep 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01972009
Sponsor's protocol ID
13HH0812
Other IDs
13/LO/1305
Status last verified
Oct 2013
First submitted
24 Oct 2013
Last updated
1 Nov 2013
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Pulmonary Hypertension, run by Imperial College London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Charlotte Manisty, MRCP PHD (+44 (0)2075841264, cmanisty@ic.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Wave reflection coefficient (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in